SPY772.04+0.09%QQQ745.40+0.12%BTC/USD84,249.00+0.19%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%
Benzinga

Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History

BEAMNASDAQ
Trade with Public
Trade with Public
$24.27
-0.39-1.58%
At close: Sep 25, 5:00 PM EST
$24.20
-0.07-0.29%
After Hours: 7:54 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Beam Therapeutics (BEAM) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$24.97
Close
$24.27
Volume / Avg.
1.22M / 2.10M
Day Range
$23.75 - $24.97
52 Wk Range
20.23 - 38.26
Market Cap
$2.49B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
40
Short Interest
38.98%
Days to Cover
12.59

Recent Beam Therapeutics Inc. News

Squeeze Watch: 10 Stocks With Over 33% Short Interest

Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
Erica Kollmann

Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
Chandrima Sanyal

These 10 Stocks Are Squeeze Candidates Waiting to Happen

These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSpark and Dutch Bros.
Erica Kollmann

Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.
Vandana Singh

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
Vandana Singh

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-359.38M
Investing Cash Flow (TTM)
189.46M
Financing Cash Flow (TTM)
107.69M
Free Cash Flow (TTM)
-372.77M
Capital Expenditure (TTM)
-13.39M
Net Change in Cash (TTM)
-62.23M

Analyst Trends and Forecast

1
May
2
Jul
1
Aug
1
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.5
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$1.60B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
16.32
PB Ratio (TTM)
2.39
Earnings Yield % (TTM)
-2.80%
Earnings Yield % (FWD)
-20.61%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$10.33

Company Debt

Total Debt
$100.26M
LT Debt
$100.26M
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$219.83M
Debt to Equity
0.23
Issuance of Debt (TTM)
$93.89M
Repayment of Debt (TTM)
-

Key Statistics

Open
$24.97
Close
$24.27
Volume / Avg.
1.22M / 2.10M
Day Range
$23.75 - $24.97
52 Wk Range
20.23 - 38.26
Market Cap
$2.49B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
40
Short Interest
38.98%
Days to Cover
12.59

About

Sector
Health Care
Industry
Biotechnology
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases....
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

Q

How do I buy Beam Therapeutics (BEAM) stock?

A

You can purchase shares of Beam Therapeutics (NASDAQ:BEAM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Beam Therapeutics (BEAM) competitors?

Q

What is the forecast, or price target, for Beam Therapeutics (BEAM) stock?

A

Beam Therapeutics has a consensus price target of $49.43.

Q

What is the current price for Beam Therapeutics (BEAM)?

A

The stock price for Beam Therapeutics (NASDAQ: BEAM) is $24.2 last updated September 25, 2026 at 7:54 PM EDT.

Q

Does Beam Therapeutics (BEAM) pay a dividend?

A

There are no upcoming dividends for Beam Therapeutics.

Q

When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?

A

Beam Therapeutics does not have any upcoming earnings scheduled.

Q

Is Beam Therapeutics (BEAM) going to split?

A

There is no upcoming split for Beam Therapeutics.

Q

What sector and industry does Beam Therapeutics (BEAM) operate in?

A

Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved